Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
410 articles
New research positions sleep EEG as an early biomarker for future neurological decline, offering a non-invasive window into brain aging.
A Mayo Clinic study reveals the Lumipulse p-tau217/Aβ42 plasma ratio has variable accuracy in detecting Alzheimer's amyloid pathology.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
Synthetic peptide chimeras degrade amyloid-beta across the blood-brain barrier, improving cognition in mice with fewer risks than current immunotherapies.
Stanford researchers found ribosome stalling in aging brain cells triggers faulty proteins and toxic clumps linked to Alzheimer's disease.
Buck Institute finds the longevity-linked APOE2 variant shields neurons from DNA damage and cellular senescence, explaining its Alzheimer's protection.
Resting-state EEG slow waves predict amyloid buildup and neurodegeneration in cognitively normal older adults, offering a non-invasive early warning tool.
Genetic variants in the water channel gene AQP4 directly affect brain volume and cognition — and interact with sleep to accelerate Alzheimer's progression.
A new genetic tracing system reveals the brain's waste-clearance routes are compartmentalized, rapid in some areas, and disrupted differently by inflammation vs. amyloid.
A neuron-specific proteasome system governs tau pathology, with APOE4 carriers showing heightened vulnerability as this system declines with age.
A new Nature Neuroscience study reveals an unexpected molecular mechanism that initiates tau aggregation, the hallmark of Alzheimer's disease.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
